#5: WHO Releases HPV Vaccine Recommendations
The World Health Organization (WHO) recently released a position paper regarding recommendations for vaccination against the most common sexually transmitted infection in the United States: human papillomavirus (HPV).
Because HPV-related diseases, such as cervical cancer, are a global health concern, WHO recommends that HPV vaccines should be “included in national immunization programs.” In addition, cervical cancer accounts for a staggering majority (84%) of HPV-associated cancers, and therefore, “should remain the priority for HPV immunization,” the authors write. The best way to prevent cervical cancer? Immunizing girls before they are sexually active.
WHO recommends that HPV vaccines should be incorporated into a “coordinated and comprehensive strategy.”
Continue reading about WHO’s HPV vaccine recommendations here
#4: FDA Approves a Once-Daily Treatment Option for HIV-1
The new approval of Isentress HD was supported by findings from the ONCEMRK phase 3 clinical trial, which included treatment-naïve patients with HIV-1. Patients were treated with once-daily Isentress HD 1200-mg (administered as two 600-mg tablets) or Isentress 400-mg twice per day plus emtricitabine + tenofovir disoproxil fumarate. Although Isentress and Isentress HD can achieve viral suppression, the drugs do not cure HIV or AIDS, according to the press release.
At 48 weeks, approximately 89% of patients treated with Isentress HD 1200-mg achieved viral suppression of HIV RNA <40 copies/mL, compared with 88% of patients treated with Isentress 400-mg twice per day, according to the study.
Through 48 weeks, only 3% of patients in both treatment groups discontinued therapy due to adverse events. This suggests that the drugs were, overall, well-tolerated. Adverse reactions of all intensities reported in the clinical trial include abdominal pain, diarrhea, vomiting, and decreased appetite.
More on the new once-daily treatment is available here